EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Publication; Inge Tetens

doi:10.2903/j.efsa.2011.2241

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Publication, Inge Tetens

28 Citations (Scopus)

Abstract

Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of a health claim in relation to melatonin and reduction of sleep onset latency. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claim is melatonin. The Panel considers that melatonin is sufficiently characterised. The claimed effects are “sleep-wake cycle regulation”, “relaxation” and “sleep patterns”. The target population is assumed to be the general population. In the context of the proposed wordings and the clarifications from Member States and the references provided, the Panel assumes that the claimed effects refer to the reduction of sleep onset latency (time taken to fall asleep). The Panel considers that reduction of sleep onset latency might be a beneficial physiological effect. In weighing the evidence, the Panel took into account that a meta-analysis of controlled human intervention studies in normal sleepers indicated a statistically significant reduction of sleep onset latency following melatonin consumption, and that these results were supported by two meta-analyses of controlled human intervention studies, one in subjects with primary sleep disorders and one in healthy subjects combined with subjects with insomnia. On the basis of the data presented, the Panel concludes that a cause and effect relationship has been established between the consumption of melatonin and reduction of sleep onset latency. The Panel considers that in order to obtain the claimed effect, 1 mg of melatonin should be consumed close to bedtime. The target population is the general population.

Original language	English

Publisher	European Food Safety Authority
DOIs	https://doi.org/10.2903/j.efsa.2011.2241
Publication status	Published - 2011
Externally published	Yes

Access to Document

10.2903/j.efsa.2011.2241

Cite this

Publication, EFSA., & Tetens, I. (2011). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. European Food Safety Authority. https://doi.org/10.2903/j.efsa.2011.2241

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. / Publication, EFSA; Tetens, Inge.

European Food Safety Authority, 2011.

Research output: Book/Report › Report › Research › peer-review

Publication, EFSA & Tetens, I 2011, EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. European Food Safety Authority. https://doi.org/10.2903/j.efsa.2011.2241

@book{71fae77f09f141458ef771e274a0c294,

title = "EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006",

abstract = "Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of a health claim in relation to melatonin and reduction of sleep onset latency. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claim is melatonin. The Panel considers that melatonin is sufficiently characterised. The claimed effects are “sleep-wake cycle regulation”, “relaxation” and “sleep patterns”. The target population is assumed to be the general population. In the context of the proposed wordings and the clarifications from Member States and the references provided, the Panel assumes that the claimed effects refer to the reduction of sleep onset latency (time taken to fall asleep). The Panel considers that reduction of sleep onset latency might be a beneficial physiological effect. In weighing the evidence, the Panel took into account that a meta-analysis of controlled human intervention studies in normal sleepers indicated a statistically significant reduction of sleep onset latency following melatonin consumption, and that these results were supported by two meta-analyses of controlled human intervention studies, one in subjects with primary sleep disorders and one in healthy subjects combined with subjects with insomnia. On the basis of the data presented, the Panel concludes that a cause and effect relationship has been established between the consumption of melatonin and reduction of sleep onset latency. The Panel considers that in order to obtain the claimed effect, 1 mg of melatonin should be consumed close to bedtime. The target population is the general population.",

author = "EFSA Publication and Inge Tetens",

year = "2011",

doi = "10.2903/j.efsa.2011.2241",

language = "English",

publisher = "European Food Safety Authority",

}

TY - RPRT

T1 - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

AU - Publication, EFSA

AU - Tetens, Inge

PY - 2011

Y1 - 2011

N2 - Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of a health claim in relation to melatonin and reduction of sleep onset latency. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claim is melatonin. The Panel considers that melatonin is sufficiently characterised. The claimed effects are “sleep-wake cycle regulation”, “relaxation” and “sleep patterns”. The target population is assumed to be the general population. In the context of the proposed wordings and the clarifications from Member States and the references provided, the Panel assumes that the claimed effects refer to the reduction of sleep onset latency (time taken to fall asleep). The Panel considers that reduction of sleep onset latency might be a beneficial physiological effect. In weighing the evidence, the Panel took into account that a meta-analysis of controlled human intervention studies in normal sleepers indicated a statistically significant reduction of sleep onset latency following melatonin consumption, and that these results were supported by two meta-analyses of controlled human intervention studies, one in subjects with primary sleep disorders and one in healthy subjects combined with subjects with insomnia. On the basis of the data presented, the Panel concludes that a cause and effect relationship has been established between the consumption of melatonin and reduction of sleep onset latency. The Panel considers that in order to obtain the claimed effect, 1 mg of melatonin should be consumed close to bedtime. The target population is the general population.

AB - Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of a health claim in relation to melatonin and reduction of sleep onset latency. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claim is melatonin. The Panel considers that melatonin is sufficiently characterised. The claimed effects are “sleep-wake cycle regulation”, “relaxation” and “sleep patterns”. The target population is assumed to be the general population. In the context of the proposed wordings and the clarifications from Member States and the references provided, the Panel assumes that the claimed effects refer to the reduction of sleep onset latency (time taken to fall asleep). The Panel considers that reduction of sleep onset latency might be a beneficial physiological effect. In weighing the evidence, the Panel took into account that a meta-analysis of controlled human intervention studies in normal sleepers indicated a statistically significant reduction of sleep onset latency following melatonin consumption, and that these results were supported by two meta-analyses of controlled human intervention studies, one in subjects with primary sleep disorders and one in healthy subjects combined with subjects with insomnia. On the basis of the data presented, the Panel concludes that a cause and effect relationship has been established between the consumption of melatonin and reduction of sleep onset latency. The Panel considers that in order to obtain the claimed effect, 1 mg of melatonin should be consumed close to bedtime. The target population is the general population.

U2 - 10.2903/j.efsa.2011.2241

DO - 10.2903/j.efsa.2011.2241

M3 - Report

BT - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

PB - European Food Safety Authority

ER -